Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 10, 2013 08:00 ET | Source: Novavax, Inc.

Novavax H7N9 VLP Influenza Vaccine Enters Animal Testing

Novavax H7N9 VLP vaccine produced, purified and entered into preclinical immunogenicity and efficacy studies in less than a month Production of GMP H7N9 clinical trial materials...
May 07, 2013 08:00 ET | Source: Novavax, Inc.

Novavax Reports First-Quarter 2013 Financial Results

Key Highlights Phase II RSV clinical trial data achieve protocol specified-objectives of safety and immunogenicity. Novel malaria vaccine candidate in India honored by the Vaccine World...
April 26, 2013 08:00 ET | Source: Novavax, Inc.

Novavax to Report First-Quarter 2013 Financial Results on May 7, 2013

ROCKVILLE, Md., April 26, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it will report its 2013 first-quarter financial results on Tuesday, May 7, 2013, before the U.S....
April 25, 2013 08:00 ET | Source: Novavax, Inc.

Novavax to Present at 12th Annual Needham Healthcare Conference

ROCKVILLE, Md., April 25, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that Stanley C. Erck, President and Chief Executive Officer of Novavax, will present a company update at...
April 15, 2013 17:14 ET | Source: Novavax, Inc.

Novavax to Review Recent Findings from Vaccine Programs at World Vaccine Congress and Expo in Washington, DC

ROCKVILLE, Md., April 15, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it will review recent clinical results from the company's vaccine development programs at the World...
April 10, 2013 08:00 ET | Source: Novavax, Inc.

Novavax Appoints Amy B. Fix Vice President of Regulatory Affairs

ROCKVILLE, Md., April 10, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced the appointment of Amy B. Fix to the position of Vice President of Regulatory Affairs. She is responsible...
April 02, 2013 16:05 ET | Source: Novavax, Inc.

Novavax Reports Positive Top-Line Results From Phase II Clinical Trial of RSV Vaccine Candidate in Women of Childbearing Age

Well-tolerated and without any vaccine related serious adverse events (SAEs) Anti-F IgG antibodies to the F protein in serum rose 6 to 16-fold across all doses (60 and 90 µg). Addition...
March 18, 2013 08:00 ET | Source: Novavax, Inc.

Novavax Reports Progress on RSV Vaccine at the XV International Symposium on Respiratory Viral Infections

ROCKVILLE, Md., March 18, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) reported that David C. Flyer, Ph.D., Director of Preclinical Development at Novavax, presented recent preclinical...
March 13, 2013 12:35 ET | Source: Novavax, Inc.

Novavax to Present at the 25th Annual ROTH Conference

ROCKVILLE, Md., March 13, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer of Novavax,...
March 08, 2013 09:30 ET | Source: Novavax, Inc.

Novavax, CPLB and ICGEB Collaboration Honored for Malaria Vaccine Progress at Vaccine World Summit India 2013

ROCKVILLE, Md., March 8, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that its collaboration to develop a novel malaria vaccine in India has been honored by the Vaccine World...